In Vitro Diagnostics Market

In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) & Region - Global Forecast to 2027

Report Code: MD 3609 Jan, 2023, by marketsandmarkets.com

The global in vitro diagnostics market in terms of revenue was estimated to be worth $117.8 billion in 2022 and is poised to reach $138.4 billion by 2027, growing at a CAGR of 3.3% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the in vitro diagnostics (IVD) market is driven by growing demand for point-of-care devices and rapid diagnostic testing, increasing prevalence of chronic diseases,  and increasing willingness to pay for preventive care testing. However, an unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

In Vitro Diagnostics Market

In Vitro Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

In Vitro Diagnostics Market

In Vitro Diagnostics Market Dynamics

Driver: Growing awareness of early disease diagnosis in emerging economies

Awareness of the disease and symptoms is essential for screening and early detection. A major reason contributing to the rapid spread of diseases is limited knowledge and awareness due to the absence, inaccessibility, or inaccuracy of information. Moreover, due to limited technology penetration and poor healthcare infrastructure, the growth of the IVD market in emerging markets was comparatively lower than in developed countries. Countries such as China, India, and other Southeast Asian countries showcase a greater growth potential due to the high prevalence of infectious diseases, large target populations, and unmet research needs for developing personalized medicines.

Restraint: unfavorable reimbursement scenario

Some infectious disease pathology tests do not have their own Healthcare Common Procedure Coding System (HCPCS) codes and are billed using unlisted codes. In such cases, Medicare Administrative Contractors (MACs) establishes a payment amount for their local jurisdictions.   Similarly, a decline and additional budgetary concerns among healthcare systems are a major obstacle to implementing novel diagnostic techniques in clinical laboratories. These changes in the reimbursement mechanism are expected to negatively affect the US molecular and genetic testing market, which may restrain the growth of the IVD market.

Opportunity: Growth opportunities in emerging countries

Developing economies such as India, China, South Korea, Brazil, Mexico, Turkey, Russia, and South Africa are expected to offer growth opportunities for major players operating in the IVD market. The Asia Pacific has emerged as an adaptive and business-friendly hub due to its relatively less-stringent regulations and data requirements. Currently, China is one of the largest investors in R&D. Moreover, as markets in the US and Europe are maturing, many players are shifting their focus to emerging markets. For instance, in 2022, Agilent Technologies (US) invested USD 20 million to expand its Shanghai manufacturing center to meet the growing demand in China for the company’s advanced liquid chromatography (LC), spectrometer, and mass spectroscopy (MS) systems.

Challenge: Stringent regulatory & legal guidelines

Regulatory requirements applied to in vitro diagnostics industry (including infectious disease diagnostics) in the US and European countries are gradually becoming more stringent. Under US federal regulations, device manufacturers must submit a 510(k) application for further modifications to a device. New applications now require software updates or new software installations in an existing device or any other changes made to these devices.

The semi-automated instruments accounted for the largest share in the in vitro diagnostics industry

Based on type, the in vitro diagnostics market is segmented into semi-automated instruments, fully automated instruments, and other instruments. In 2021, the semi-automated instruments segment accounted for the largest share of the market. The large share of this segment can be attributed to its compact tabletop size, ease of use, and cost-effectiveness as compared to fully-automated instruments.

The rapid tests segment accounted for the largest share of the in vitro diagnostics industry for immunochemistry/immunoassay

Based on type, immunochemistry/immunoassay is segmented into enzyme-linked immunosorbent assay, radioimmunoassays, rapid tests, western blotting, and enzyme- linked immunospot assays. In 2021, the rapid tests segment dominated this market. The adoption of rapid tests has increased due to their ability to provide testing in remote areas or emergencies where no sophisticated or advanced technology is available for disease screening. This supports market growth.

The oncology segment of the in vitro diagnostics industry to register the highest growth during the forecast period

Based on the application, the in vitro diagnostics market has been segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/ pharmacogenomics, HIV/ AIDS, autoimmune diseases, nephrology, and other applications. The oncology segment held the largest share in 2021. The increasing number of cancer cases worldwide, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth for the oncology segment.

The large reference laboratories segment accounted for the largest share of the in vitro diagnostics industry for clinical laboratories

Based on type, the clinical laboratories is segmented into large reference laboratories, medium-sized reference laboratories, and small laboratories. In 2021, the large reference laboratories segment accounted for the largest share of the in vitro diagnostics market for clinical laboratories. The large reference laboratories offer various advantages over small- and medium-sized laboratories and hospital laboratories, including complex and specialized testing capabilities, and broad test panels with testing on various samples. These factors attribute to the large share of this market.

North America accounted for the largest share of the in vitro diagnostics industry in 2021

The in vitro diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa. North America accounted for the largest share in the in vitro diagnostics industry in 2021. The large share of this region can primarily be attributed to the increasing investments in healthcare, the presence of a well-developed healthcare infrastructure, and the growing adoption of advanced healthcare technologies in the region.

In Vitro Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key players in the in vitro diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), bioMérieux SA (France), Agilent Technologies, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Chembio Diagnostics, Inc.  (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US).

Scope of the In Vitro Diagnostics Industry:

Report Metric

Details

Market Revenue in 2023

$117.8 billion

Estimated Value by 2028

$138.4 billion

Revenue Rate

Poised to grow at a CAGR of 3.3%

Market Driver

Growing awareness of early disease diagnosis in emerging economies

Market Opportunity

Growth opportunities in emerging countries

The study categorizes the in vitro diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product and Service

  • Reagents & Kits
  • Services
  • Instruments
  • Data Management Software

By Application

  • Infectious diseases
  • Diabetes
  • Drug Testing/ Pharmacogenomics
  • Autoimmune diseases
  • Oncology
  • Cardiology
  • HIV/AIDS
  • Nephrology
  • Other applications

By Technology

  • Immunoassay/ Immunochemistry
  • Clinical chemistry
  • Hematology
  • Molecular diagnostics
  • Microbiology
  • Coagulation and Hemostasis
  • Urinalysis
  • Other Technologies

By End User

  • Hospital laboratories
  • Point-of-care testing centers
  • Academic institutes
  • Clinical laboratories
  • Patients
  • Other end users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • Saudi Arabia
    • Rest of Middle East & Africa

Recent Developments of In Vitro Diagnostics Industry

  • In November 2022, Thermo Fisher Scientific (US) launched the rapid RT-PCR Accula Flu A/Flu B Test designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes.
  • In October 2022, Thermo Fisher Scientific (US) entered a definitive agreement to acquire The Binding Site Group, a global leader in specialty diagnostics. The Binding Site provides specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders
  • In September 2022, Sysmex Corporation (Japan) launched the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500) for urine sediment testing. The UF-1500 inherits the high levels of functionality and usability of the UF-5000 Fully Automated Urine Particle Analyzer (UF-5000).
  • In August 2022, Al-Futtaim Health (Dubai) and Abbott Laboratories (US) entered into a strategic partnership to improve the standards of advanced laboratory diagnostics in Dubai.
  • In February 2022, Sysmex Corporation (Japan) opened a new subsidiary, Sysmex LLC, in Saudi Arabia. With this local subsidiary providing direct sales, Sysmex aims further to reinforce its sales and service structure in Saudi Arabia.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 43)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
           1.2.2 MARKET SEGMENTATION
                    FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY CONSIDERED 
          TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 48)
    2.1 RESEARCH APPROACH 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
          FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2021)
          FIGURE 8 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS INDUSTRY (2021)
          FIGURE 9 IVD MARKET: TOP-DOWN APPROACH
          FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2022–2027)
          FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET
    2.3 DATA TRIANGULATION APPROACH 
          FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 STUDY ASSUMPTIONS 
    2.6 LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 62)
    FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 IN VITRO DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 IN VITRO DIAGNOSTICS INDUSTRY, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 GEOGRAPHIC SNAPSHOT OF IVD MARKET
 
4 PREMIUM INSIGHTS (Page No. - 66)
    4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 18 RISING INCIDENCE OF INFECTIOUS DISEASES AND GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED ANALYZERS TO DRIVE MARKET
    4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE AND COUNTRY (2021) 
          FIGURE 19 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
    4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.4 IN VITRO DIAGNOSTICS INDUSTRY: GEOGRAPHIC MIX 
          FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING VS. DEVELOPED MARKETS 
          FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 70)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases
                                TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)
                    5.2.1.2 Gradual shift from centralized testing to point-of-care testing
                    5.2.1.3 Growing awareness of early disease diagnosis in emerging economies
                    5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers
                                TABLE 4 IN VITRO DIAGNOSTICS INDUSTRY: PRODUCT LAUNCHES (2020−2022)
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Introduction of disease-specific biomarkers and tests
                                TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE
                    5.2.3.2 Growing significance of companion diagnostics
                    5.2.3.3 Growth opportunities in emerging markets
                                TABLE 6 RECENT DEVELOPMENTS IN EMERGING MARKETS
           5.2.4 CHALLENGES
                    5.2.4.1 Stringent regulatory & legal guidelines
                                FIGURE 24 IVDR: KEY AREAS OF IMPACT
                    5.2.4.2 Operational barriers
                                TABLE 7 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 INDUSTRY TRENDS 
           5.3.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES
           5.3.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING
           5.3.3 RISING NUMBER OF REAGENT RENTAL AGREEMENTS
           5.3.4 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS
             FIGURE 25 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS
    5.4 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 8 PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET
           5.4.1 INTENSITY OF COMPETITIVE RIVALRY
           5.4.2 BARGAINING POWER OF SUPPLIERS
           5.4.3 BARGAINING POWER OF BUYERS
           5.4.4 THREAT OF NEW ENTRANTS
           5.4.5 THREAT FROM SUBSTITUTES
    5.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 
          TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.6 REGULATORY ANALYSIS 
           5.6.1 NORTH AMERICA
                    5.6.1.1 US
                                TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                                FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.6.1.2 Canada
                                FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
           5.6.2 EUROPE
                    TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
                    FIGURE 28 EUROPE: IVDR TIMELINE
           5.6.3 ASIA PACIFIC
                    5.6.3.1 Japan
                                FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN
                                TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
                                TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.6.3.2 China
                                TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.6.3.3 India
                                FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.6.3.4 South Korea
                                TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.6.3.5 Indonesia
                                TABLE 16 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           5.6.4 RUSSIA
                    TABLE 17 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.6.5 MIDDLE EAST & AFRICA
                    5.6.5.1 Saudi Arabia
                                TABLE 18 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.6.5.2 Africa
           5.6.6 LATIN AMERICA
                    5.6.6.1 Mexico
                                FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                                TABLE 19 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.6.6.2 Brazil
    5.7 KEY CONFERENCES & EVENTS IN 2023 
          TABLE 20 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.8 PATENT ANALYSIS 
           5.8.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 32 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2022)
                    FIGURE 33 TOP APPLICANT JURISDICTIONS FOR IVD PATENTS (JANUARY 20211-DECEMBER 2022)
           5.8.2 PATENT PUBLICATION TRENDS FOR IN VITRO DIAGNOSTICS INDUSTRY
                    FIGURE 34 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2022)
                    TABLE 21 LIST OF PATENTS/PATENT APPLICATIONS IN IVD MARKET, 2021–2022
    5.9 TRADE ANALYSIS 
           5.9.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS
                    TABLE 22 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (USD MILLION)
                    TABLE 23 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (TONS)
    5.10 ECOSYSTEM ANALYSIS 
           FIGURE 35 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET
           5.10.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
    5.11 VALUE CHAIN ANALYSIS 
           FIGURE 36 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS INDUSTRY
    5.12 SUPPLY CHAIN ANALYSIS 
           FIGURE 37 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET
    5.13 PRICING ANALYSIS 
           5.13.1 INDICATIVE AVERAGE SELLING PRICE (USD) REGION-WISE: REAGENTS & KITS
           5.13.2 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS
           5.13.3 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS
           5.13.4 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS
    5.14 TECHNOLOGY ANALYSIS 
           5.14.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
           5.14.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET
    5.15 CASE STUDY 
           FIGURE 38 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
    5.16 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
                      FIGURE 39 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS
                      TABLE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS (%)
           5.16.2 BUYING CRITERIA
                      FIGURE 40 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
                      TABLE 25 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS
    5.17 IMPACT OF RECESSION ON IVD MARKET (2021–2024) 
    5.18 IMPACT OF IN VITRO DIAGNOSTIC REGULATIONS (IVDR) ON LABORATORY TESTING 
 
6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 111)
    6.1 INTRODUCTION 
          TABLE 26 IN VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 REAGENTS & KITS 
           6.2.1 GROWING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET
                    TABLE 27 IVD MARKET FOR REAGENTS & KITS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 INSTRUMENTS 
          TABLE 28 KEY INSTRUMENTS AVAILABLE IN IVD MARKET
          TABLE 29 IVD MARKET FOR INSTRUMENTS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 30 IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 FULLY AUTOMATED INSTRUMENTS
                    6.3.1.1 Rising availability of technologically advanced analyzers to drive market
                                 TABLE 31 IVD MARKET FOR FULLY AUTOMATED INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.2 SEMI-AUTOMATED INSTRUMENTS
                    6.3.2.1 Compact design and cost-effectiveness over automated analyzers to support market growth
                                 TABLE 32 IVD MARKET FOR SEMIAUTOMATED INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.3 OTHER INSTRUMENTS
                    TABLE 33 IVD MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 DATA MANAGEMENT SOFTWARE 
           6.4.1 GROWING ADOPTION OF AUTOMATED ANALYZERS AND RISING NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET
                    TABLE 34 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET
                    TABLE 35 IVD MARKET FOR DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
    6.5 SERVICES 
           6.5.1 RISING NEED TO ENSURE EFFECTIVE UTILISATION OF IVD PRODUCTS TO SUPPORT MARKET GROWTH
                    TABLE 36 IVD MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 124)
    7.1 INTRODUCTION 
          TABLE 37 IN VITRO DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    7.2 IMMUNOASSAY/IMMUNOCHEMISTRY 
          TABLE 38 KEY IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN IVD MARKET
          TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 40 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
                    TABLE 41 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET
                    TABLE 42 IVD MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 43 IVD MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.1 Chemiluminescence Immunoassays
                               7.2.1.1.1 Rising technological advancements and continuous product innovations to drive segment growth
                                              TABLE 44 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
                                              TABLE 45 IVD MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.2 Fluorescence Immunoassays
                               7.2.1.2.1 Rising demand for low-cost fluorescent dyes to drive segment growth
                                              TABLE 46 KEY FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
                                              TABLE 47 IVD MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
                    7.2.1.3 Colorimetric Immunoassays
                               7.2.1.3.1 High specificity and easy coagulation to antibodies to drive segment growth
                                              TABLE 48 KEY COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET
                                              TABLE 49 IVD MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.2 RADIOIMMUNOASSAYS
                    7.2.2.1 Usage of RIAs in cancer detection, blood screening, and drug discovery to drive market
                                TABLE 50 IVD MARKET FOR RADIOIMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.3 RAPID TESTS
                    7.2.3.1 Rising usage of rapid tests for emergency care to drive market
                                TABLE 51 KEY RAPID TESTS AVAILABLE IN IVD MARKET
                                TABLE 52 IVD MARKET FOR RAPID TESTS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.4 WESTERN BLOTTING
                    7.2.4.1 Widely accepted technique for result validation to support market growth
                                TABLE 53 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET
                                TABLE 54 IVD MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2020–2027 (USD MILLION)
           7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT)
                    7.2.5.1 High sensitivity and adaptability of technology to fuel market adoption
                                TABLE 55 IVD MARKET FOR ELISPOT ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 CLINICAL CHEMISTRY 
          TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
          TABLE 57 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
          TABLE 58 KEY BLOOD GAS ANALYZERS AVAILABLE IN IVD MARKET
          TABLE 59 IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 60 CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.1 BASIC METABOLIC PANELS
                    7.3.1.1 Set of blood tests performed to ascertain common acute conditions
                                TABLE 61 IVD MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.2 LIVER PANELS
                    7.3.2.1 Panels used to identify and monitor liver diseases & injuries
                                TABLE 62 IVD MARKET FOR LIVER PANELS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.3 RENAL PROFILES
                    7.3.3.1 Panels used to monitor cytokines & chemokines in urine
                                TABLE 63 IVD MARKET FOR RENAL PROFILES, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.4 LIPID PROFILES
                    7.3.4.1 Lipid panel testing determines total cholesterol and risk status for CVD
                                TABLE 64 IVD MARKET FOR LIPID PROFILES, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.5 THYROID FUNCTION PANELS
                    7.3.5.1 Tests performed to determine TSH and thyroglobulin
                                TABLE 65 IVD MARKET FOR THYROID FUNCTION PANELS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.6 ELECTROLYTE PANELS
                    7.3.6.1 Prescribed for symptoms such as edema, nausea, and cardiac arrhythmia
                                TABLE 66 IVD MARKET FOR ELECTROLYTE PANELS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.3.7 SPECIALTY CHEMICAL TESTS
                    7.3.7.1 Test profile includes immunosuppressant drug monitoring and drugs of abuse
                                TABLE 67 IVD MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 MOLECULAR DIAGNOSTICS 
          TABLE 68 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET
          TABLE 69 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 70 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.1 POLYMERASE CHAIN REACTION (PCR)
                    7.4.1.1 Rising prevalence of infectious & viral diseases to drive market
                                TABLE 71 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET
                                TABLE 72 IVD MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
                    7.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth
                                TABLE 73 IVD MARKET FOR INAAT, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.3 HYBRIDIZATION
                    7.4.3.1 Advanced hybridization & automation of data collection techniques to support market growth
                                TABLE 74 IVD MARKET FOR HYBRIDIZATION, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
                    7.4.4.1 Rising demand for personalized medicine to support market growth
                                TABLE 75 KEY NGS INSTRUMENTS AVAILABLE IN IVD MARKET
                                TABLE 76 IVD MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.5 MICROARRAYS
                    7.4.5.1 High throughput & resolution capabilities to drive market for protein expression profiling
                                TABLE 77 IVD MARKET FOR MICROARRAYS, BY COUNTRY, 2020–2027 (USD MILLION)
           7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
                    TABLE 78 IVD MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 HEMATOLOGY 
           7.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS TO DRIVE MARKET
                    TABLE 79 KEY HEMATOLOGY ANALYZERS AVAILABLE IN IVD MARKET
                    TABLE 80 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 MICROBIOLOGY 
           7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
                    TABLE 81 KEY MICROBIOLOGY INSTRUMENTS AVAILABLE IN IVD MARKET
                    TABLE 82 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 COAGULATION & HEMOSTASIS 
           7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET
                    TABLE 83 KEY COAGULATION ANALYZERS AVAILABLE IN IVD MARKET
                    TABLE 84 KEY POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN IVD MARKET
                    TABLE 85 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.8 URINALYSIS 
           7.8.1 RISING PREVALENCE OF KIDNEY DISORDERS AND UTIS TO DRIVE MARKET
                    TABLE 86 KEY URINALYSIS INSTRUMENTS AVAILABLE IN IVD MARKET
                    TABLE 87 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.9 OTHER TECHNOLOGIES 
          TABLE 88 KEY BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN IVD MARKET
          TABLE 89 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN IVD MARKET
          TABLE 90 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 174)
    8.1 INTRODUCTION 
          TABLE 91 IN VITRO DIAGNOSTICS INDUSTRY, BY APPLICATION, 2020–2027 (USD MILLION)
    8.2 INFECTIOUS DISEASES 
           8.2.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE ADOPTION OF IVD PRODUCTS
                    TABLE 92 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 DIABETES 
           8.3.1 RISING PREVALENCE OF DIABETES TO DRIVE ADOPTION OF GLUCOSE MONITORING DEVICES
                    TABLE 93 COUNTRIES WITH A DIABETIC PATIENT POPULATION, 2021 VS. 2045 (MILLION)
                    TABLE 94 IVD MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 ONCOLOGY 
           8.4.1 RISING INITIATIVES FOR EARLY DETECTION OF CANCER TO DRIVE MARKET
                    TABLE 95 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.5 CARDIOLOGY 
           8.5.1 INCREASING USE OF IMMUNOASSAYS IN DETECTION OF CVD TO DRIVE MARKET
                    TABLE 96 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.6 DRUG TESTING/PHARMACOGENOMICS 
           8.6.1 INCREASING USE OF TOXICOLOGY TESTING FOR ILLICIT DRUGS TO DRIVE MARKET
                    TABLE 97 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.7 HIV/AIDS 
           8.7.1 INCREASING USAGE OF REAL-TIME PCR TESTS FOR HIV DETECTION TO DRIVE MARKET
                    TABLE 98 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.8 AUTOIMMUNE DISEASES 
           8.8.1 GROWING DEMAND FOR PORTABLE POC DIAGNOSTIC DEVICES TO DRIVE MARKET
                    TABLE 99 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.9 NEPHROLOGY 
           8.9.1 INCREASING USE OF BIOMARKERS FOR CKD TO SUPPORT MARKET GROWTH
                    TABLE 100 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    8.10 OTHER APPLICATIONS 
           TABLE 101 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 IN VITRO DIAGNOSTICS MARKET, BY END USER (Page No. - 188)
    9.1 INTRODUCTION 
          TABLE 102 IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 HOSPITAL LABORATORIES 
           9.2.1 RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INFECTIOUS DISEASES TO DRIVE MARKET
                    TABLE 103 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 CLINICAL LABORATORIES 
          TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 105 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.1 LARGE REFERENCE LABORATORIES
                    9.3.1.1 Capability to conduct specific tests such as LDTs with advanced diagnostic tools to drive segment growth
                                TABLE 106 LARGE REFERENCE LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.2 MEDIUM-SIZED LABORATORIES
                    9.3.2.1 Increasing adoption of automated instruments to drive growth of this segment
                                TABLE 107 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           9.3.3 SMALL LABORATORIES
                    9.3.3.1 Adoption of point-of-care devices to support segment growth
                                TABLE 108 SMALL LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 POINT-OF-CARE TESTING CENTERS 
           9.4.1 RISING DEMAND FOR RAPID TESTING AND AVAILABILITY OF INNOVATIVE POINT-OF-CARE IVD PRODUCTS TO DRIVE MARKET
                    TABLE 109 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.5 PATIENTS 
           9.5.1 USE OF CONVENIENT SELF-TEST KITS TO DRIVE MARKET
                    TABLE 110 IVD MARKET FOR PATIENTS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.6 ACADEMIC INSTITUTES 
           9.6.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 111 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.7 OTHER END USERS 
          TABLE 112 IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 IN VITRO DIAGNOSTICS MARKET, BY REGION (Page No. - 202)
     10.1 INTRODUCTION 
             FIGURE 41 IN VITRO DIAGNOSTICS INDUSTRY: GEOGRAPHIC SNAPSHOT (2021)
             TABLE 113 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 42 NORTH AMERICA: IVD MARKET SNAPSHOT
             TABLE 114 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 115 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 116 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 117 NORTH AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 118 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 119 NORTH AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 120 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Established reimbursement framework and favorable policies for IVD providers to drive market
                        TABLE 121 US: MACROECONOMIC INDICATORS
                        TABLE 122 US: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 123 US: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 124 US: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 125 US: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 126 US: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 127 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising government initiatives & funding for early disease diagnosis to drive market
                        TABLE 128 CANADA: ESTIMATED PREVALENCE OF DIABETES
                        TABLE 129 CANADA: MACROECONOMIC INDICATORS
                        TABLE 130 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 131 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 132 CANADA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 133 CANADA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 134 CANADA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 135 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             TABLE 136 EUROPE: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 137 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 138 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 139 EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 140 EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 141 EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 142 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Growing investments in clinical diagnostics research to drive market
                                      TABLE 143 GERMANY: MACROECONOMIC INDICATORS
                                      TABLE 144 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 145 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 146 GERMANY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 147 GERMANY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 148 GERMANY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 149 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.2 FRANCE
                        10.3.2.1 High healthcare expenditure and rising investments in genomic medicine to drive market
                                      TABLE 150 FRANCE: MACROECONOMIC INDICATORS
                                      TABLE 151 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 152 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 153 FRANCE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 154 FRANCE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 155 FRANCE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 156 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Rising adoption of genome-based testing and increasing accessibility to IVD tests to drive market
                                      TABLE 157 UK: MACROECONOMIC INDICATORS
                                      TABLE 158 UK: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 159 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 160 UK: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 161 UK: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 162 UK: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 163 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
                                      TABLE 164 ITALY: MACROECONOMIC INDICATORS
                                      TABLE 165 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 166 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 167 ITALY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 168 ITALY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 169 ITALY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 170 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Rising adoption of technologically advanced immunoassay systems to drive market
                                      TABLE 171 SPAIN: MACROECONOMIC INDICATORS
                                      TABLE 172 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 173 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 174 SPAIN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 175 SPAIN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 176 SPAIN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 177 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.6 RUSSIA
                        10.3.6.1 Rising incidence of non-communicable diseases and government support for medical services to support market growth
                                      TABLE 178 RUSSIA: MACROECONOMIC INDICATORS
                                      TABLE 179 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 180 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 181 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 182 RUSSIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 183 RUSSIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 184 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 185 REST OF EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 186 REST OF EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 187 REST OF EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 188 REST OF EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 189 REST OF EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 190 REST OF EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 43 ASIA PACIFIC: IVD MARKET SNAPSHOT
             TABLE 191 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 192 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 193 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 194 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 195 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 196 ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 197 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Universal healthcare reimbursement policy and research investments for immunoassays to support market growth
                                      TABLE 198 JAPAN: MACROECONOMIC INDICATORS
                                      TABLE 199 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 200 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 201 JAPAN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION))
                                      TABLE 202 JAPAN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 203 JAPAN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 204 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing awareness of preventive care to drive market for advanced & rapid testing platforms
                                      TABLE 205 CHINA: MACROECONOMIC INDICATORS
                                      TABLE 206 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 207 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 208 CHINA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 209 CHINA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 210 CHINA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 211 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising incidence of diabetes and cancer to fuel market growth for IVD products
                                      TABLE 212 INDIA: MACROECONOMIC INDICATORS
                                      TABLE 213 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 214 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 215 INDIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 216 INDIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 217 INDIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 218 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Rising healthcare spending for innovative IVD technologies to support market growth
                                      TABLE 219 SOUTH KOREA: MACROECONOMIC INDICATORS
                                      TABLE 220 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 221 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 222 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 223 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 224 SOUTH KOREA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 225 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.5 INDONESIA
                        10.4.5.1 Increasing healthcare initiatives and rising burden of infectious diseases to drive market
                                      TABLE 226 INDONESIA: MACROECONOMIC INDICATORS
                                      TABLE 227 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 228 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 229 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 230 INDONESIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 231 INDONESIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 232 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.4.6 REST OF ASIA PACIFIC
                        TABLE 233 REST OF ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 234 REST OF ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 235 REST OF ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 236 REST OF ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 237 REST OF ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 238 REST OF ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA 
             TABLE 239 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 240 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 241 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 242 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 243 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 244 LATIN AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 245 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.5.1 BRAZIL
                        10.5.1.1 Improving healthcare infrastructure to support adoption of IVD products
                                      TABLE 246 BRAZIL: MACROECONOMIC INDICATORS
                                      TABLE 247 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 248 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 249 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 250 BRAZIL: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 251 BRAZIL: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 252 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.5.2 MEXICO
                        10.5.2.1 Improving accessibility and affordability to healthcare services to support market growth
                                      TABLE 253 MEXICO: MACROECONOMIC INDICATORS
                                      TABLE 254 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 255 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 256 MEXICO: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 257 MEXICO: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 258 MEXICO: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 259 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.6.2 REST OF MIDDLE EAST & AFRICA
                        TABLE 280 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 281 REST OF MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 282 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 283 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 284 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 285 REST OF MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
             TABLE 267 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
             TABLE 268 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
             TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
             TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
             TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
             TABLE 272 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.6.1 SAUDI ARABIA
                        10.6.1.1 Rising government healthcare expenditure to support adoption of IVD products
                                      TABLE 273 SAUDI ARABIA: MACROECONOMIC INDICATORS
                                      TABLE 274 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 275 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 276 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 277 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                                      TABLE 278 SAUDI ARABIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                                      TABLE 279 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
             10.6.2 REST OF MIDDLE EAST & AFRICA
                        TABLE 280 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
                        TABLE 281 REST OF MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 282 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 283 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
                        TABLE 284 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)
                        TABLE 285 REST OF MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 293)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             FIGURE 44 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN IVD MARKET
     11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 
             FIGURE 45 REVENUE ANALYSIS FOR KEY PLAYERS IN IVD MARKET
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 46 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
             TABLE 286 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION
             11.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY
                        11.4.1.1 Clinical chemistry
                                      FIGURE 47 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.2 Immunochemistry/immunoassay analyzers
                                      FIGURE 48 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.3 Microbiology
                                      FIGURE 49 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.4 Molecular diagnostics
                                      FIGURE 50 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.5 Hematology
                                      FIGURE 51 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.6 Coagulation & hemostasis
                                      FIGURE 52 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
                        11.4.1.7 Urinalysis
                                      FIGURE 53 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021)
     11.5 R&D ASSESSMENT OF KEY PLAYERS 
     11.6 COMPETITIVE BENCHMARKING 
             TABLE 287 IN VITRO DIAGNOSTIC MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS
     11.7 COMPANY EVALUATION QUADRANT 
             11.7.1 STARS
             11.7.2 PERVASIVE PLAYERS
             11.7.3 EMERGING LEADERS
             11.7.4 PARTICIPANTS
                        FIGURE 54 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT 2021
     11.8 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS 
             11.8.1 PROGRESSIVE COMPANIES
             11.8.2 DYNAMIC COMPANIES
             11.8.3 STARTING BLOCKS
             11.8.4 RESPONSIVE COMPANIES
                        FIGURE 55 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR SMES & STARTUPS
     11.9 COMPANY FOOTPRINT ANALYSIS 
             TABLE 288 IVD MARKET: COMPANY FOOTPRINT
             TABLE 289 COMPANY FOOTPRINT: BY PRODUCT & SERVICE
             TABLE 290 COMPANY FOOTPRINT: BY TECHNOLOGY
             TABLE 291 COMPANY FOOTPRINT: BY APPLICATION
             TABLE 292 COMPANY FOOTPRINT: BY END USER
     11.1 COMPETITIVE SCENARIO 
             11.10.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 293 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–DECEMBER 2022
             11.10.2 DEALS
                        TABLE 294 DEALS, JANUARY 2019–DECEMBER 2022
             11.10.3 OTHER DEVELOPMENTS
                        TABLE 295 OTHER DEVELOPMENTS, JANUARY 2019–DECEMBER 2022
 
12 COMPANY PROFILES (Page No. - 314)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 KEY PLAYERS 
             12.1.1 ROCHE DIAGNOSTICS
                        TABLE 296 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 56 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
             12.1.2 DANAHER CORPORATION
                        TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.3 ABBOTT LABORATORIES, INC.
                        TABLE 298 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 58 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.4 SIEMENS HEALTHINEERS
                        TABLE 299 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 59 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021)
             12.1.5 SYSMEX CORPORATION
                        TABLE 300 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 60 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.6 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 301 THERMO FISHER SCIENTIFIC, INC: BUSINESS OVERVIEW
                        FIGURE 61 THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT (2021)
             12.1.7 BECTON, DICKINSON AND COMPANY
                        TABLE 302 BD: BUSINESS OVERVIEW
                        FIGURE 62 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             12.1.8 BIOMÉRIEUX SA
                        TABLE 303 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 63 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             12.1.9 BIO-RAD LABORATORIES, INC.
                        TABLE 304 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW
                        FIGURE 64 BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT (2021)
             12.1.10 AGILENT TECHNOLOGIES, INC.
                        TABLE 305 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 65 AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021)
             12.1.11 QIAGEN N.V.
                        TABLE 306 QIAGEN N.V.: BUSINESS OVERVIEW
                        FIGURE 66 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
             12.1.12 QUIDEL CORPORATION
                        TABLE 307 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 67 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.13 DIASORIN S.P.A.
                        TABLE 308 DIASORIN S.P.A: BUSINESS OVERVIEW
                        FIGURE 68 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
             12.1.14 ILLUMINA, INC.
                        TABLE 309 ILLUMINA, INC: BUSINESS OVERVIEW
                        FIGURE 69 ILLUMINA, INC: COMPANY SNAPSHOT (2021)
             12.1.15 HOLOGIC, INC.
                        TABLE 310 HOLOGIC, INC: BUSINESS OVERVIEW
                        FIGURE 70 HOLOGIC, INC: COMPANY SNAPSHOT (2021)
     12.2 OTHER PLAYERS 
             12.2.1 DEVYSER
                        TABLE 311 DEVYSER: BUSINESS OVERVIEW
                        FIGURE 71 DEVYSER: COMPANY SNAPSHOT (2021)
             12.2.2 PERKINELMER INC.
                        TABLE 312 PERKINELMER, INC: BUSINESS OVERVIEW
                        FIGURE 72 PERKINELMER, INC: COMPANY SNAPSHOT (2021)
             12.2.3 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 313 CHEMBIO DIAGNOSTICS, INC: BUSINESS OVERVIEW
                        FIGURE 73 CHEMBIO DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021)
             12.2.4 SURMODICS, INC.
                        TABLE 314 SURMODICS, INC: BUSINESS OVERVIEW
                        FIGURE 74 SURMODICS, INC: COMPANY SNAPSHOT (2022)
             12.2.5 MENARINI SILICON BIOSYSTEMS
                        TABLE 315 MENARINI SILICON BIOSYSTEMS: BUSINESS OVERVIEW
             12.2.6 SPEEDX PTY. LTD.
             12.2.7 GENSPEED BIOTECH GMBH
             12.2.8 ACCELERATE DIAGNOSTICS, INC.
             12.2.9 MERCK KGAA
             12.2.10 CARIS LIFE SCIENCES, INC.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 454)
     13.1 INSIGHTS FROM INDUSTRY EXPERTS 
     13.2 DISCUSSION GUIDE 
     13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.4 CUSTOMIZATION OPTIONS 
     13.5 RELATED REPORTS 
     13.6 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global in vitro diagnostics market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply side and other participants were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the in vitro diagnostics industry. The primary sources from the other participants group including hospital personells, laboratory staff, C-level executives, department heads, clinical staffs, and personnel from CROs. And others including, private consultants, suppliers, distributers and officials from government regulatory bodies.

A breakdown of the primary respondents is provided below:

In-Vitro Diagnostics Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2021: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by products & services, technology, application, end user, and region).

Data Triangulation

After arriving at the market size, the total in vitro diagnostics market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast the in vitro diagnostics market by product & services, technology, application, end user, and by region.
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall in vitro diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the in vitro diagnostics market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the in vitro diagnostics market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions, FDA approvals, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the in vitro diagnostics market
  • To benchmark players within the IVD market using the “Company Evaluation Quadrant” framework, which analyzes market players on various parameters within categories of business strategies, market share, and product offerings

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Geographic Analysis

  • Further breakdown of the in vitro diagnostics market in the Rest of the Asia Pacific
  • Further breakdown of the in vitro diagnostics market in the Rest of Latin America
  • Further breakdown of the in vitro diagnostics market in the Rest of the Middle East & Africa
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3609
Published ON
Jan, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the In Vitro Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback